Clinical Trials
3 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04535102 2022-05-09
POLA+BR for Relapsed or Refractory DLBCL
University of Colorado, Denver
Phase 2 Withdrawn
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn